For adults with acute symptoms of schizophrenia, newer and older antipsychotics that are available in Europe or the United States reduced overall symptoms and resulted in lower all-cause discontinuation rates compared with placebo; however, there were large differences in adverse events between treatments, according to study results published in Lancet.
Investigators conducted a network meta-analysis of placebo-controlled and head-to-head randomized controlled trials in adults with acute symptoms of schizophrenia or related disorders. In addition, they compared and ranked 32 antipsychotic agents. The primary outcome was change in overall schizophrenia symptoms. Secondary outcomes included discontinuation (either all-cause or due to inefficacy); changes in positive, negative, and depressive symptoms; quality of life; and social functioning.
1 Like